Answers are grounded in this paper and cite their sources.
Background Clinical Immune Phenotyping and Explainable Risk Modeling for Lung Cancer (CIPHER-Lung) is a rule-based peripheral blood immune score that organizes measured biomarkers into clinically readable concepts. We assessed whether these concepts outperform constituent markers, remain stable under assay-like computational perturbations, and identify discordance with standard disease burden. Methods This retrospective exploratory internal evaluation used 260 sample records from de-identified participants in an existing institutional cohort. Overall-survival analyses included 162 patients with lung cancer and 73 deaths, and only 31 had all six markers. The primary available-concept score combined the measured subset of a six-marker panel into four phenotypic proxies: loss of T-cell surveillance, checkpoint activation/terminal differentiation, cytokine inflammation, and hematology/myeloid inflammation. The fixed formula was applied without outcome-based coefficient refitting. Analyses included matched marker comparisons, clinical benchmarking, inverse-probability-of-censoring weighted (IPCW) evaluation, concept ablation, limited adaptation, computational jitter dropout, and 24-month discordance phenotyping. Results The available-concept score had a Harrell C-index of 0.697 and IPCW cumulative/dynamic AUROCs of 0.765 and 0.764 at 12 and 24 months. On matched participants, the composite exceeded CD3, CD8+PD-1+, CD8+CD57+, and the cytokine concept, whereas the NLR/hematology concept performed similarly in its smaller subset. The supplied fixed weighting did not outperform unweighted aggregation. Training-fold calibration and a four-concept linear probe produced only modest gains over the fixed score. Under five-point concept jitter plus 10% dropout, the median C-index was 0.691, rank correlation was 0.939, and high-risk agreement was 0.912. Descriptive point estimates were higher for clinical models. The combined model showed no material point-estimate gain over the clinical model. Paired intervals for clinical-model comparisons were unavailable. Conclusions CIPHER-Lung provides an interpretable immune-state representation supported by this retrospective exploratory internal evaluation. The score is not supported for stand-alone diagnosis, treatment selection, or replacement of stage and performance status. Candidate uses in longitudinal phenotyping, enrichment, or point-of-care reporting require complete-marker multicenter validation, documented reference standards, analytical qualification, external calibration, and prospective impact studies.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: